Scott Moorefield, Ph.D., is Silverback’s senior vice president of business development. Prior to Silverback, Scott was the chief business officer at Boundless Bio, a company developing therapies targeting the role of extrachromosomal DNA (ecDNA) in driving oncogene amplifications, where he led the startup’s day-to-day operations, business development, and corporate strategy. Before Boundless, he was at Roche/Genentech where he served in roles of increasing responsibility across business development, development, and commercial organizations. Most recently he was the director of oncology business development, focused on bringing in targeted therapies for driver mutations and tumor agnostic approaches to oncology. In that role, he was actively involved in several deals, including leading the acquisition of Ignyta for $2 billion in February 2018. Prior to Roche/Genentech, he was a life science consultant for Campbell Alliance. Scott holds a B.S. in biology and chemistry from the University of North Carolina, Chapel Hill. After completing his Ph.D. in molecular oncology and genomic sciences from North Carolina State University, he was a postdoctoral fellow in the neurosurgery department at the University of California San Francisco.